Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

US: BIO meets the press: economic health of the biotech industry; follow-on biologics; patent reform (Patent Docs) (Patent Docs) (Intellectual Property Watch)

Vinorelbine ditartrate – Belgium: Brussels Court of First Instance rules on whether SPC protection extends to use of an active ingredient before it is transformed into medicinal product (The SPC Blog)

Practicalities of paediatric extensions – a recent article (The SPC Blog)

Africa: South African researchers complain University of Maryland patented Maasai higher milk tolerance gene mutations collected from Kenya, Tanzania, Sudan and South Africa (Afro-IP)

EU: European Commission to post submissions on website in wake of inquiry into pharmaceutical sector (Pharmacapsules @ Gowlings) (Managing Intellectual Property)

EU Commission proposal on counterfeit drugs (Pharmacapsules @ Gowlings)

India: Why did the government of India oppose the ‘counterfeit drug’ definition proposed by IMPACT? (Spicy IP)

Kenya enacts Biosafety Act 2/2009 regulating activities in GMOs, establishing National Biosafety Authority (Afro-IP)

US: BIO meets the press: economic health of the biotech industry; follow-on biologics; patent reform (Patent Docs) (Patent Docs) (Intellectual Property Watch)

US: Obama touts generic biologics to lower drug costs (Law360)

US: Genentech announces victory in Cabilly re-examination (Patent Docs)

US: Federal judge rejects Scruggs family’s bid to reconsider summary judgment in favour of Monsanto over unauthorised use of patented Roundup Ready seeds but chance for appeal (Law360)

US: Monsanto’s view on patent reform – protect innovation (Patently-O)

Androgel (Testosterone) – Canada: Court upholds decision of Minister not to list patent on Patent Register: Solvay v Canada (Minister of Health) (Pharmacapsules @ Gowlings)

Celebrex (Celecoxib) – Canada: Court dismisses appeal of patent delisting proceeding: G D Searle v Canada (Pharmacapsules @ Gowlings)

Cellcept (Mycophenolate) – US: Yet another petition submitted to FDA concerning the QI Act and 30-month stay availability; latest is petition from Hoffmann-La Roche concerning Cellcept (FDA Law Blog)

Cipramil (Citalopram) – UK: House of Lords rules crucial patent law terms are not synonymous: Generics (UK) Ltd & Ors v H Lundbeck A/S (Out-Law)

Deximune (Ciclosporin) – UK: Purposive, not linguistic interpretation is the right way, says High Court judge: Novartis AG v Dexcel-Pharma Ltd (PatLit)

Emend (Aprepitant) – US: Merck sues Sandoz over plan for generic Emend (Law360)

Ferrochel (Ferrous bis-glycinate chelate) – US: Lannett, Albion spar over generic vitamins (Law360)

Glivec (Imatinib) – India: Ducking TRIPS in India: Novartis ‘Glivec’ case and s 3(d) (Spicy IP)

Glucosamine – US: ITC institutes investigation regarding non-shellfish derived glucosamine, following complaint lodged by Cargill (ITC 337 Law Blog)

Neurontin (Gabapentin) – US: Plaintiffs, including Smithfield Foods, voluntarily dismiss all claims against Pfizer in consolidated class action accusing Pfizer of engaging in anti-competitive scheme to delay generic Neurontin (Law360)

Nexavar (Sorefanib) – India: Bayer vs Cipla/Union of India: Attempting ‘patent linkage’ in India (Spicy IP) (Spicy IP) (Spicy IP) (Spicy IP)

Opana (Oxymorphone) – US: Penwest and Endo announces settlement of Opana patent litigation (Patent Docs)

Valcyte (Valganciclovir) – India: Supreme Court orders Roche not to pursue patent infringement case until post-grant oppositions resolved; Discussion of pre-grant objections against Roche’s Valganciclovir patent application (Spicy IP) (Spicy IP)

Viagra (Sildenafil) – Canada: Court of Appeal upholds trial judge’s decision prohibiting Apotex from entering market until expiry of patent: Apotex v Pfizer (Pharmacapsules @ Gowlings)

Vinorelbine ditartrate – Belgium: Brussels Court of First Instance rules on whether SPC protection extends to use of an active ingredient before it is transformed into medicinal product (The SPC Blog)

Vyvanse (Lisdexamfetamine) – US: Actavis sues FDA over Vyvanse exclusivity; action challenges FDA’s new chemical entity (NCE) exclusivity policies (FDA Law Blog)